Mohammad Aminur Rahman
Overview
Explore the profile of Mohammad Aminur Rahman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
611
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Wang D, Peng S, Amin A, Rahman M, Nannapaneni S, Liu Y, et al.
PLoS One
. 2016 Dec;
11(12):e0168450.
PMID: 28033401
The anti-tumor effect of a chelating phen-based ligand 2,9-di-sec-butyl-1,10-phenanthroline (dsBPT) and its combination with cisplatin were examined in both lung and head and neck cancer cell lines and xenograft animal...
12.
Majumdar D, Rahman M, Chen Z, Shin D
Front Biosci (Elite Ed)
. 2016 Apr;
8(3):358-69.
PMID: 27100344
Sexually transmitted oral cancer/head and neck cancer is increasing rapidly. Human papilloma virus (HPV) is playing a role in the pathogenesis of a subset of squamous cell carcinoma of head...
13.
Md Anisuzzaman A, Haque A, Rahman M, Wang D, Fuchs J, Hurwitz S, et al.
Cancer Prev Res (Phila)
. 2015 Oct;
9(1):63-73.
PMID: 26511491
Despite its high promise for cancer prevention and therapy, the potential utility of curcumin in cancer is compromised by its low bioavailability and weak potency. The purpose of the current...
14.
Rahman M, Shin D
Clin Cancer Res
. 2015 Oct;
21(20):4499-501.
PMID: 26473185
In their review article published in the March 1, 2008, issue of Clinical Cancer Research, Cho and colleagues presented the strong potential of nanotechnology in cancer. This commentary discusses the...
15.
Amin A, Haque A, Rahman M, Chen Z, Khuri F, Shin D
PLoS One
. 2015 Apr;
10(4):e0124218.
PMID: 25910231
Curcumin, a natural compound isolated from the Indian spice "Haldi" or "curry powder", has been used for centuries as a traditional remedy for many ailments. Recently, the potential use of...
16.
Haque A, Rahman M, Chen Z, Saba N, Khuri F, Shin D, et al.
Apoptosis
. 2015 Apr;
20(7):986-95.
PMID: 25860284
Combinatorial approaches using two or more compounds are gaining increasing attention for cancer therapy. We have previously reported that the combination of the EGFR-TKI erlotinib and epigallocatechin-3-gallate (EGCG) exhibited synergistic...
17.
Jiang N, Wang D, Hu Z, Shin H, Qian G, Rahman M, et al.
Mol Cancer Ther
. 2014 Apr;
13(7):1826-36.
PMID: 24748655
The EGFR monoclonal antibody cetuximab is the only approved targeted agent for treating head and neck squamous cell carcinoma (HNSCC). Yet resistance to cetuximab has hindered its activity in this...
18.
Rahman M, Amin A, Wang D, Koenig L, Nannapaneni S, Chen Z, et al.
Clin Cancer Res
. 2013 May;
19(13):3416-28.
PMID: 23719266
Purpose: Ribonucleotide reductase subunit M2 (RRM2) plays an active role in tumor progression. Recently, we reported that depletion of RRM2 by systemic delivery of a nanoparticle carrying RRM2-specific siRNA suppresses...
19.
Wang D, Muller S, Amin A, Huang D, Su L, Hu Z, et al.
Clin Cancer Res
. 2012 Jul;
18(17):4589-99.
PMID: 22829201
Purpose: This study aimed to understand the prognostic value of integrin β1 expression in head and neck squamous cell carcinoma (HNSCC) and the mechanism underlying its association with metastatic HNSCC....
20.
Rahman M, Amin A, Wang X, Zuckerman J, Choi C, Zhou B, et al.
J Control Release
. 2012 Feb;
159(3):384-92.
PMID: 22342644
Systemic delivery of siRNA to solid tumors remains challenging. In this study, we investigated the systemic delivery of a siRNA nanoparticle targeting ribonucleotide reductase subunit M2 (RRM2), and evaluated its...